問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2010-01-01 - 2012-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2007-05-01 - 2010-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2022-06-16 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2010-12-01 - 2013-04-30

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2006-08-01 - 2009-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2008-08-01 - 2011-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2010-07-01 - 2013-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-12-01 - 2022-12-31

Phase II

Completed
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer

  • Condition/Disease

    Advanced Biliary Tract Cancer

  • Test Drug

    OPDIVO

Participate Sites
7Sites

Recruiting7Sites

2017-04-01 - 2025-11-04

Phase III

Completed
A randomized, Phase 3, controlled study of a regorafenib-containing regimen versus standard therapy in patients with refractory advanced gastroesophageal cancer (AGOC).

  • Condition/Disease

    Advanced gastroesophageal cancer (AGOC)

  • Test Drug

    Regorafenib (BAY 73-4506)

Participate Sites
5Sites

Recruiting5Sites

2020-09-01 - 2025-05-14

Phase I

Completed
Phase Ib, Multi-center Study of Combining Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary Central Nervous System Lymphoma.

  • Condition/Disease

    Primary Central Nervous System Lymphoma (PCNSL)

  • Test Drug

    Acalabrutinib

Participate Sites
4Sites

Recruiting4Sites

1 34 35 36 37 38 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB